Next Article in Journal
Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review
Previous Article in Journal
L-Serine Influences Epigenetic Modifications to Improve Cognition and Behaviors in Growth Hormone-Releasing Hormone Knockout Mice
Previous Article in Special Issue
Fecal Bacterial Community and Metagenome Function in Asians with Type 2 Diabetes, According to Enterotypes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 11
Issue 1
10.3390/biomedicines11010105
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Genetic Ablation of the Nutrient Sensor Ogt in Endocrine Progenitors Is Dispensable for β-Cell Development but Essential for Maintenance of β-Cell Mass

by
Alicia Wong
1,
Brian Akhaphong
2,
Daniel Baumann
2 and
Emilyn U. Alejandro
2,*
1
Department of Genetics, Cell Biology, and Development, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA
2
Department of Integrative Biology and Physiology, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2023, 11(1), 105; https://doi.org/10.3390/biomedicines11010105
Submission received: 8 December 2022 / Revised: 20 December 2022 / Accepted: 29 December 2022 / Published: 30 December 2022
(This article belongs to the Special Issue Pathological Mechanisms in Diabetes)
Browse Figures
Review Reports Versions Notes

Abstract

:
Previously we utilized a murine model to demonstrate that Ogt deletion in pancreatic progenitors (OgtKOPanc) causes pancreatic hypoplasia, partly mediated by a reduction in the Pdx1-expressing pancreatic progenitor pool. Here, we continue to explore the role of Ogt in pancreas development by deletion of Ogt in the endocrine progenitors (OgtKOEndo). At birth OgtKOEndo, were normoglycemic and had comparable pancreas weight and α-cell, and β-cell mass to littermate controls. At postnatal day 23, OgtKOEndo displayed wide ranging but generally elevated blood glucose levels, with histological analyses showing aberrant islet architecture with α-cells invading the islet core. By postnatal day 60, these mice were overtly diabetic and showed significant loss of both α-cell and β-cell mass. Together, these results highlight the indispensable role of Ogt in maintenance of β-cell mass and glucose homeostasis.

1. Introduction

The enzyme O-GlcNAc Transferase (Ogt) catalyzes the attachment of the O-GlcNAc post translational modification onto Serine and Threonine residues on nuclear, cytosolic proteins, and mitochondrial proteins [1,2,3,4]. This attachment is removed by the enzyme, O-GlcNAcase (Oga), whose namesake gene contains a diabetes susceptibility locus in humans [5]. UDP-GlcNAc, the substrate for Ogt, is synthesized through the glucose-sensitive Hexosamine Biosynthesis Pathway (HBP) [6]. Distinct from other forms of protein glycosylation, the addition and removal of an O-GlcNAc modification can occur many times at different rates throughout the lifespan of a single polypeptide [7] and is sensitive to changes in cellular environment, such as the influx of nutrients [8]. Aberrations in O-GlcNAcylation have been linked with the development of metabolic diseases such as Type 2 Diabetes [9,10,11,12], and assessment of global O-GlcNAcylation levels has been shown to be a potential early biomarker of insulin resistance in humans [13].
While expressed in all mammalian tissues, Ogt is most abundant in the pancreas [14], and within the adult murine model, it is mostly highly expressed in the pancreatic islets [15]. Pancreas development is tightly governed by a hierarchy of transcriptional activation. Starting in the foregut endoderm, a pool of Pdx1+ pancreatic progenitors gives rise to both the endocrine (Islets of Langerhans) and exocrine (acinar) pancreas compartments [16]. In the mature pancreas, Pdx1 is only expressed in the β-cells [17]. Some transcription factors are O-GlcNAc modified by Ogt [18], including Pdx1 [19,20]. Previously, we demonstrated that O-GlcNAcylation in the pancreatic epithelium is required for pancreas organogenesis in mice. Deletion of Ogt in the developing epithelium resulted in pancreatic hypoplasia due, in part, to increased apoptosis and a reduction in the Pdx1+ pancreatic progenitor pool [20]. In the β-cells, ablation of Ogt led to reduced β-cell mass and increased ER stress-mediated apoptosis [15]. Using both murine and human islets, we previously demonstrated that O-GlcNAcylation of sarco/endoplasmic reticulum Ca2+-ATPase, SERCA2, in the islet is required for lipid potentiation of insulin secretion, a hallmark of β-cell adaptation to hyperlipidemia and obesity prior to the onset of Type 2 Diabetes [21]. Many transcription factors that play an important role in β-cell function in response to glucose stimulus, such as cAMP-responsive element-binding protein (CREB), and Pdx1, have been demonstrated to be O-GlcNAc modified, and the modification is known to affects their activity [19,22]. O-GlcNAcylation of several components of the insulin signaling pathway, such as insulin receptor substrate 1 (IRS-1), has been shown to attenuate insulin signaling under a normoglycemic context [23]. On the other hand, hyper-O-GlcNAcylation in the β-cells also results in β-cell dysfunction [24]. Taken together, control of O-GlcNAcylation levels is important for pancreas development and the maintenance of β-cell function, adaptation, and glucose homeostasis. We hypothesized that the O-GlcNAc modification of transcription factors at the endocrine development stage is required for the formation of functional pancreatic islets.
Using an endocrine-cell Ogt-deficient mouse model (OgtKOEndo), we demonstrate that Ogt is not required for the formation of pancreatic islets. However, OgtKOEndo develop aberrant islet architecture and progressive hyperglycemia early in life, followed by severe loss of α-cell mass and β-cell mass in adulthood. Taken together, these data highlight the requirement of Ogt in the maintenance of functional β-cell mass.

2. Methods

2.1. Animals

Neurogenin3-cre (Ngn3), Ogtflox/flox, and CAG-EGFP reporter transgenic animals were purchased from The Jackson Laboratory. Ngn3-cre; Ogtf/+ (OgtHETEndo) females were crossed with Ogtf/y males to produce OgtHETEndo, OgtKOEndo, and controls (Ogtflox/+, Ogtflox/flox, Ogtflox/y, or Ngn3-cre; Ogt WT). All mice were generated on a C57Bl6/J background and group-housed on a 14:10 light:dark cycle. Experiments were performed with both male and female mice (unless otherwise stated), and data was combined for neonatal experiments and separated in adolescent and adult experiments.

2.2. Blood and Tissue Collection

Neonatal mice were sacrificed by decapitation at postnatal day 0. P23, p28, and p60 mice were sacrificed by CO2 asphyxiation, and death was confirmed via a hard toe pinch followed by cervical dislocation. Pancreas and spleen were collected following a V-incision to open the abdominal cavity then microdissected under a gross morphology microscope. Whole blood and blood glucose readings were collected via the trunk at sacrifice for neonates and via tail vein for p23, p28, and p60 mice.

2.3. Serum Insulin Analysis

Non-fasting serum insulin levels were assessed using Rat or Mouse Ultrasensitive Insulin ELISA kit (Alpco Diagnostics, Salem, NH, USA) using mouse insulin standards and following manufacturer’s instructions. Serum was extracted from whole blood collected at sacrifice.

2.4. Glucose Tolerance Test

Mice were fasted overnight for 14 h followed by an intraperitoneal injection of sterile glucose at a concentration of 2 g/kg body weight. Blood glucose readings were assessed prior to injection and at 30, 60, and 120 min post-injection via tail vein using a handheld glucometer, which has an upper limit of 600 mg/dL. Any values above 600 mg/dL were calculated using blood diluted 1/5.

2.5. Tissue Preparation and Immunofluorescence Staining

Tissues harvested at dissection were treated in 3.7% formaldehyde for 12 h at 4 degrees C, rehydrated in 70% ethanol, and processed for paraffin embedding using the Leica ASP300S. Neonatal tissue was sectioned from top to bottom at 5 μm thickness. Tissues from p23, p28, and p60 were sectioned at 5 microns thickness representing 5 regions spaced 200 μm apart as previously described [25]. Deparaffinization was performed via Citrisolv and ethanol baths, and heat-based antigen retrieval was conducted 3 × 4 min at 95 degrees C using a sodium citrate solution. Tissues were permeabilized via TritonX-100 in PBS, followed by blocking using Roche Blocking Reagent (Sigma, St. Louis, MO, USA). Tissues were stained using primary antibodies against guinea pig insulin (DAKO, Santa Clara, CA, USA, 1:400), mouse glucagon (Abcam, Cambridge, UK, 1:500), rabbit Pdx1 (Abcam, 1:400), and rabbit synaptophysin (Abcam, 1:400) and incubated overnight at 4 degrees C followed by treatment with FitC (1:400), Cy3 (1:500), or Alexa647 (1:100)-conjugated secondary antibodies. Nuclei were counterstained by dipping in DAPI (1:1000 in PBS). TUNEL apoptotic staining was completed using the ApopTag Red in situ Apoptosis Detection Kit per manufacturer’s instructions (Millipore, Burlington, MA, USA).

2.6. Cell Counts and Morphometric Analysis

All cell counts and morphometric analysis were performed using FIJI/ImageJ [26] using the thresholding, masking, and object counter as previously described [20]. Fluorescence images were captured using the Nikon Eclipse NI-E epifluorescence microscope (Nikon Instruments, Melville, NY, USA) at 4× (gross morphology), 10× (β-cell and α-cell area and mass), 20× (islet morphology), and 40× (islet cell counts). All cell counts represent at least 1000 cells per mouse. Cell type was identified using hormone+ area by immunofluorescence, which was used to quantify α-cell area, β-cell area, and pancreas area in FIJI/ImageJ [26]. α and β-cell mass was conducted by averaging insulin+ area or glucagon+ area over pancreas area across five sections throughout the pancreas, then correcting this global average by pancreas weight.

2.7. Statistical Analysis

Statistical analysis was conducted in Prism 8.4.3 for windows (GraphPad Software, San Diego, CA, USA, www.graphpad.com (accessed on 7 December 2022)) via Mann–Whitney U-Test with p ≤ 0.05 deemed significant and 0.05 < p < 0.1 deemed trending. All values are expressed as mean ± SEM.

3. Results

3.1. Deletion of Ogt in the Endocrine Progenitors Has No Effect on Islet Formation

To assess the effect of Ogt on the formation of the islet cells, we used a cre-lox system driven by the Neurogenin-3 (Ngn3) promoter, to genetically ablate Ogt in all cells of neuroendocrine origin (OgtKOEndo). We assessed these mice at birth (postnatal day (p) 0). Both heterozygous and homozygous deletion of Ogt resulted in no differences in gross pancreas morphology (Figure 1A). OgtKOEndo displayed similar body weight, pancreas weight, and blood glucose as littermate controls (Figure 1B–D), along with comparable β-cell mass and α-cell mass (Figure 1E,F). These parameters were also comparable between OgtHETEndo and controls (Figure S1A–E). Both islet morphology (and pancreas morphology were normal in OgtKOEndo (Figure 1G and Figure S1F). Because programmed cell death is involved in the remodeling of neonatal islets [27], we also assessed apoptosis in the newborn islets via immunofluorescence. Staining by TUNEL showed similarly low levels of apoptosis in the β-cells of OgtKOEndo and control (Figure 1H,I). Endogenous GFP cre-reporter expression was robust and specific to pancreatic endocrine cells, indicating high efficiency of the Ngn3-cre (Figure 1J). Taken together, these data indicate that Ogt is not required for the formation of endocrine cells.

3.2. Progressive Loss of β-Cell Mass and Reduced Immunoreactivity of Pdx1 in OgtKOEndo

To determine the effect of Ogt in the maintenance of glucose homeostasis, we tracked various parameters of OgtKOEndo from p15 through p28. At p15-17, both male and female OgtKOEndo exhibit comparable body weight and non-fasting blood glucose to littermate controls, though OgtKOEndo females showed a non-significant trend toward lower blood glucose (Figure 2A,B and Figure S2A,B p = 0.0952). At p28, male OgtKOEndo show similar body weight, absolute pancreas weight, and pancreas/body weight ratio compared to littermate controls (Figure 2C–E). However, female OgtKOEndo exhibit a non-significant trend toward decreased body weight at this age (Figure S2C p = 0.0686). In line with this, while absolute pancreas weight was comparable, pancreas weight corrected over body weight was reduced in female OgtKOEndo (Figure S2D,E). Both male and female OgtKOEndo have elevated non-fasting blood glucose at p28 but have comparable serum insulin levels (Figure 2F,G and Figure S2F,G). Since blood glucose and serum insulin levels were similar between male and female at p28, we performed histological analyses in male mice only. OgtKOEndo have reduced insulin-positive area relative to whole pancreas area (Figure 2H) and a non-significant trend toward reduced β-cell mass (Figure 2I p = 0.0556). In contrast to β-cell specific Ogt-deficient mice, OgtKOEndo mice also exhibited trends in reduced glucagon+ area and α-cell mass (Figure 2J p = 0.0635, K p = 0.1111). Because Pdx1 expression in β-cells is positively correlated with function and survival, we assessed Pdx1 protein expression via immunofluorescence. Staining with Pdx1 antibody suggested reduced immunoreactivity of Pdx1 in the OgtKOEndo (Figure 2L). Pdx1 exerts its activity as a transcription factor primary in the nucleus. Interestingly, in islets of OgtKOEndo mice, some cells express Pdx1 in the cytoplasm (Figure 2L).

3.3. Aberrations in Islet Architecture in OgtKOEndo at Weaning

Because OgtKOEndo are normoglycemic at p15-17 by hyperglycemic at p28, we assessed these mice at the intermediate age of p23 to assess the presence of transitional changes within the islet. At p22–24, both male and female OgtKOEndo have similar body weight, absolute pancreas weight, and pancreas weight/body weight ratio as controls (Figure 3A–C and Figure S2H–J). However, both male and female OgtKOEndo display elevated, albeit more variable, non-fasting blood glucose levels (Figure 3D and Figure S2K), with comparable but more variable serum insulin levels (Figure 3E and Figure S2L). Since both male and female mice were metabolically similar at this age, we performed histological analyses only in male mice. Both insulin+ area /pancreas area and β-cell mass were comparable between OgtKOEndo and littermate controls (Figure 3F,G). Interestingly, while glucagon+ area/pancreas area and α-cell mass were not different between OgtKOEndo and control (Figure 3H,I), the proportion of glucagon+ cells per islet was reduced (Figure 3J). Islet architecture in these mice was also perturbed, with α-cells invading the islet core (Figure 3K), but exocrine pancreas morphology was unchanged (Figure S2M).

3.4. Adult OgtKOEndo Are Diabetic and Have Both Reduced β-Cell Mass and α-Cell Mass

Sex hormones are known to play a role in regulating glucose homeostasis. Thus, we wanted to assess OgtKOEndo mice at sexual maturity. We first confirmed robust expression of Ngn3-cre in adults via visualization of GFP cre-reporter expression in p60 mice and showed that cre expression colocalized with both α-cells and the β-cells (Figure 4A). No differences in exocrine morphology were observed between OgtKOEndo and controls (Figure S3A), and pancreas weight and spleen weight were comparable to controls (Figure 4B,C). Both male and female OgtKOEndo displayed severely elevated blood glucose levels (Figure 4D and Figure S3B), with a corresponding decrease in body weight over time (Figure 4E). Both male and female OgtKOEndo were severely glucose intolerant and unable to normalize blood glucose levels following in intraperitoneal injection of glucose (Figure 4F and Figure S3C). Because no differences in glucose homeostasis were observed between males and females, histological analyses were performed in male mice only. As expected, both β-cell mass and α-cell mass were severely reduced in OgtKOEndo (Figure 4G–I). In instances of massive β-cell mass loss, other islet cells such as the somatostatin-producing δ-cells have been shown to transdifferentiate into β-like cells in compensation [28]. To assess whether this was occurring in the OgtKOEndo, we performed immunofluorescence staining of pancreas sections using synaptophysin, a marker of cells of neuroendocrine origin. We did not find a substantial population of synaptophysin-expressing cells outside of the insulin and glucagon positive islets in the OgtKOEndo (Figure S3D).

4. Discussion

We have previously shown the requirement of Ogt in the developing epithelium in pancreas formation, but the role of Ogt in development of the pancreatic endocrine cells was unknown [20]. Here, we genetically ablated Ogt in the pancreatic endocrine progenitors and characterized the morphological and metabolic phenotypes using mice. We found that while Ogt is not required for formation of the endocrine pancreas at birth, it is indispensable for the maintenance of both islet architecture and β-cell and α-cell mass and, consequently, glucose homeostasis (Figure 5).

4.1. Role of Islet Protein O-GlcNAcylation in Glucose Homeostasis

In the pancreas, nutrient-sensitive O-GlcNAcylation occurs at a relatively higher level in the islets than in the acinar [15]. In the β-cell, both hypo and hyper-O-GlcNAcylation increases susceptibility to metabolic stress and β-cell dysfunction [15,24,29], suggesting modulation of O-GlcNAc levels is necessary to maintain β-cell function. In the α-cells, deletion of Ogt leads to defects in both glucagon secretion and gluconeogenesis but does not affect whole body glucose homeostasis as measured by glucose tolerance or insulin sensitivity tests, and fasting glucose and insulin levels [30]. Deletion of Ogt in β-cells or α-cells do not impair peripheral insulin sensitivity as measured by insulin tolerance test via ip injection [15,30]. In the present study, Ogt was simultaneously deleted in all endocrine cells, including both α-cells and β-cells. It is known that β-cell-specific ablation of Ogt leads to hyperglycemia in male mice at approximately 10 weeks of age and females at 15 weeks [15]. In this study, however, hyperglycemia occurs in both males and females by p23 (3 weeks of age), indicating that disruption of O-GlcNAcylation in multiple cell types at once accelerates the development of hyperglycemia. It is known that different islet cell types communicate via paracrine signaling to sustain normoglycemia [31]. For example, insulin signaling in the α-cells has been shown to regulate glucagon secretion [32]. Likewise, blocking the glucagon receptors in transplanted human islets in mice results in increased blood glucose levels and reduced insulin levels in vivo [31], and treatment of human islets with glucagon strongly potentiates glucose-stimulated insulin secretion in vitro [33]. It is surmisable that concurrently deleting Ogt in multiple islet cell types perturbs cell to cell communication and leads to swift defects in function.

4.2. Maintenance of the α-Cell and β-Cell Population

Ablation of Ogt in either the β-cells or the α-cells results in reduced β-cell mass and α-cell mass, respectively [15,20]. In the β-cell Ogt deletion model, preliminary data at one moth of age suggests α-cell mass was not perturbed (data not shown). This is in line with evidence indicating β-cells and α-cells differentiate from separate cell lineages in adults [34], suggesting perturbation of one cell type, specifically, does not occur at the detriment of the other. In the present study, we demonstrate that simultaneous deletion of Ogt in all endocrine cells results in progressive loss of both β-cell mass and α-cell mass without upregulation of other islet cell types. This suggests Ogt may also be required in the functional mass of other pancreatic endocrine cell types and is an interesting direction for future study.

4.3. Pro-Survival Role of Ogt in the Endocrine Cells

Pdx1 is a master regulator of β-cell development, identity, and function [35]. In the postnatal pancreas, Pdx1 expression is restricted to the β-cells [17]. Expression of Pdx1 potentiates transcription of the insulin gene and represses an α-cell program [36,37]. Depletion of Pdx1 results in increased apoptosis in the islet, demonstrating the pro-survival role of Pdx1 [38]. Interestingly, we and others have demonstrated that Pdx1 is O-GlcNAc modified by Ogt [19,20] and that mice with Ogt-deficiency in the β-cells have reduced Pdx1 protein levels and increased ER stress-mediated apoptosis [15], suggesting Ogt regulates cell survival through Pdx1. Reconstitution of Pdx1 partially improves pancreatic and β-cell mass deficits in mice lacking Ogt in their pancreatic progenitors [39]. In the present study, we demonstrate that at p28, OgtKOEndo mice displayed reduced immunoreactivity to Pdx1. These mice go on to become severely glucose intolerant, with near-complete loss of β-cell mass, suggesting Pdx1-dependent apoptosis is a potential mechanism of the progressive β-cell mass and serum insulin reduction in the OgtKOEndo. The pool of Pdx1+ cells is also a determinant of the population of other islet cell types [40]. Mice with β-cell specific Pdx1-deficiency display aberrant islet architecture [40]. In the present study, islets of OgtKOEndo mice also show differences in islet architecture, with α-cells invading the core of the islet (a common phenotype in diabetic islets), suggesting that in the progression toward islet cell loss, deletion of Ogt perturbs islet organization, in part, by reduction of Pdx1. Islet apoptosis and Pdx1 protein levels are potential areas of exploration in a future study.

4.4. Temporal Role of Ogt in Regulation of Pancreas Development

We previously demonstrated that expression of Ogt at the pancreatic progenitor stage (OgtKOPanc) is necessary for both endocrine and exocrine pancreas development. Ablation of Ogt at this stage results in severe pancreatic hypoplasia [20]. In the present study, Ogt was deleted in the endocrine progenitors, which arise later in development (OgtKOEndo). Unlike OgtKOPanc mice, OgtKOEndo are born with normal exocrine and endocrine pancreas compartments, like the β-cell-specific or α-cell specific Ogt knockout [15,30]. This suggest that Ogt plays a crucial role in pancreas organogenesis prior to endocrine specification, after which Ogt is dispensable. This temporal nature of Ogt’s regulation in pancreas development may point to the critical windows in development during which O-GlcNAcylation of transcription factors is essential for progenitor cell survival (Figure 5).

4.5. Limitations of the Study

We cannot rule out the effects on glucose metabolism of Ogt deletion in extra-pancreatic tissues (i.e., hypothalamus) where the Ngn3 Cre driver may also be expressed [41]. Thus, one limitation of the current study is the expression of the Ngn3 promoter in hypothalamic neurons [42] and in the duodenum [43], where Ogt loss has been associated with obesity and reduced body weight in adult mice, respectively. We monitored body weight in our studies, and we have not observed any changes in body weight phenotypes in OgtKOIns, OgtKOEndo, or OgtKOPanc that cannot be attributed to the onset of hyperglycemia. Additionally, this study is a preliminary, preclinical assessment on pancreas development and the programming of islet susceptibility to Type 2 Diabetes with limited animal cohorts. The effect of nutrient-sensitive post-translational modifications of transcription factors in the developing human exocrine and endocrine pancreas warrants further exploration.

4.6. Speculation on Clinical Utility of Present Data

An individual’s susceptibility to glucose intolerance is determined by genetic, epigenetic, and environmental factors. Genome Wide Association Studies (GWAS) have identified genetic loci associated with β-cell function and glucose-stimulated insulin release as Type 2 Diabetes susceptibility alleles [44]. This suggests that β-cells’ ability to functionally compensate in response to insulin demand is a tipping point in determining whether an individual will develop Type 2 Diabetes. Obesity is a major risk factor in developing Type 2 Diabetes [45]. Human islets from male obese BMI donors exhibit higher insulin secretion in response to glucose stimulation when there is higher islet O-GlcNAcylation while lower islet O-GlcNAcylation is associated with diminished islet stimulation index compared to a lean BMI donor control [21], suggesting upregulation of islet O-GlcNAcylation is a potential functional adaptation to increased insulin demand associated with hyperlipidemia.
During pancreas development, the availability of nutrients in the intrauterine environment is known to program offspring metabolic health and susceptibility to obesity and metabolic syndromes [46] but also influences flux through the HBP and, consequently, levels of O-GlcNAcylation. Many transcription factors that regulate pancreas development and the maintenance of β-cell identity and function, such as Pdx1, are putatively O-GlcNAc modified [19]. This is a potential mechanistic link between nutrient-dependent post-translational modifications and the programming of offspring metabolic function, an avenue that warrants further study. In addition, while hemoglobin A1c (HbA1c) test is a common test to diagnose prediabetes and diabetes, measuring levels of O-GlcNAc-modified proteins in the blood has recently emerged as a more sensitive biomarker of early-stage metabolic dysfunction in young, metabolically normal adults and was positively correlated with insulin resistance (HOMA-IR) [13]. Thus, measurement of O-GlcNAc levels in conjunction with other standard clinical tests such as glucose tolerance and HbA1cc tests may be an avenue to explore to detect individuals with early onset of the disease to maximize effective treatment or prevention.

5. Concluding Remarks

While it is known that deletion of Ogt in the pancreatic β-cells or α-cells leads to defects in β-cell and α-cell function, respectively, the effect of simultaneous ablation of Ogt in all pancreatic endocrine cells has not been reported. We demonstrate that while Ogt expression in the pancreatic endocrine progenitors is not required for the formation of the islets at birth, it is essential for the regulation of glucose homeostasis through maintenance of functional α-cell and β-cell mass, highlighting the temporal role of Ogt in regulating pancreas development (Figure 5).

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biomedicines11010105/s1, Figure S1: Both OgtHETEndo and OgtKOEndo are normal at birth; Figure S2: Female OgtKOEndo develop progressive hyperglycemia over time, Figure S3. Loss of α and β-cell mass in OgtKOEndo is not compensated by other pancreatic endocrine cells.

Author Contributions

Conceptualization, E.U.A.; Methodology, A.W., B.A., D.B. and E.U.A.; Software, A.W., B.A., D.B. and E.U.A.; Validation, A.W., B.A., E.U.A. and D.B.; Formal Analysis, A.W., B.A., D.B. and E.U.A.; Investigation, A.W., B.A., D.B. and E.U.A.; Resources, E.U.A.; Data Curation, A.W., B.A., D.B. and E.U.A.; Writing—Original Draft Preparation, A.W. and E.U.A.; Writing—Review/Editing, A.W., E.U.A., D.B. and B.A.; Visualization, A.W., B.A., D.B. and E.U.A.; supervision, E.U.A.; project administration, E.U.A.; funding acquisition, E.U.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the National Institutes of Health (R21DK112144 and R01DK115720 to E.U.A., T32GM140936 to A.W., 3R03DK114465-01A1S1 to B.A., 5T32DK083250-13 to D.B.), University of Minnesota Foundation, and McKnight Foundation.

Institutional Review Board Statement

All procedures were performed in accordance with the University of Minnesota Institutional Animal Care and Use Committee (Protocol Number# 2106A39213).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data available at request.

Acknowledgments

We acknowledge Jop van Berlo for providing access to tissue processing and embedding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Torres, C.R.; Hart, G.W. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J. Biol. Chem. 1984, 259, 3308–3317. [Google Scholar] [CrossRef]
  2. Holt, G.D.; Hart, G.W. The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J. Biol. Chem. 1986, 261, 8049–8057. [Google Scholar] [CrossRef] [PubMed]
  3. Hanover, J.A.; Yu, S.; Lubas, W.B.; Shin, S.H.; Ragano-Caracciola, M.; Kochran, J.; Love, D.C. Mitochondrial and nucleocytoplasmic isoforms of O-linked GlcNAc transferase encoded by a single mammalian gene. Arch. Biochem. Biophys. 2003, 409, 287–297. [Google Scholar] [CrossRef] [PubMed]
  4. Shin, S.H.; Love, D.C.; Hanover, J.A. Elevated O-GlcNAc-dependent signaling through inducible mOGT expression selectively triggers apoptosis. Amino Acids 2011, 40, 885–893. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Lehman, D.M.; Fu, D.J.; Freeman, A.B.; Hunt, K.J.; Leach, R.J.; Johnson-Pais, T.; Hamlington, J.; Dyer, T.D.; Arya, R.; Abboud, H.; et al. A single nucleotide polymorphism in MGEA5 encoding O-GlcNAc-selective N-acetyl-beta-D glucosaminidase is associated with type 2 diabetes in Mexican Americans. Diabetes 2005, 54, 1214–1221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Chaveroux, C.; Sarcinelli, C.; Barbet, V.; Belfeki, S.; Barthelaix, A.; Ferraro-Peyret, C.; Lebecque, S.; Renno, T.; Bruhat, A.; Fafournoux, P.; et al. Nutrient shortage triggers the hexosamine biosynthetic pathway via the GCN2-ATF4 signalling pathway. Sci. Rep. 2016, 6, 27278. [Google Scholar] [CrossRef] [Green Version]
  7. Slawson, C.; Housley, M.P.; Hart, G.W. O-GlcNAc cycling: How a single sugar post-translational modification is changing the way we think about signaling networks. J. Cell. Biochem. 2006, 97, 71–83. [Google Scholar] [CrossRef]
  8. Zachara, N.E.; Hart, G.W. O-GlcNAc a sensor of cellular state: The role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim. Biophys. Acta 2004, 1673, 13–28. [Google Scholar] [CrossRef]
  9. Dias, W.B.; Hart, G.W. O-GlcNAc modification in diabetes and Alzheimer’s disease. Mol. Biosyst. 2007, 3, 766–772. [Google Scholar] [CrossRef]
  10. Buse, M.G. Hexosamines, insulin resistance, and the complications of diabetes: Current status. Am. J. Physiol. Endocrinol. Metab. 2006, 290, E1–E8. [Google Scholar] [CrossRef]
  11. Copeland, R.J.; Bullen, J.W.; Hart, G.W. Cross-talk between GlcNAcylation and phosphorylation: Roles in insulin resistance and glucose toxicity. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E17–E28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Slawson, C.; Copeland, R.J.; Hart, G.W. O-GlcNAc signaling: A metabolic link between diabetes and cancer? Trends Biochem. Sci. 2010, 35, 547–555. [Google Scholar] [CrossRef] [Green Version]
  13. Myslicki, J.P.; Shearer, J.; Hittel, D.S.; Hughey, C.C.; Belke, D.D. O-GlcNAc modification is associated with insulin sensitivity in the whole blood of healthy young adult males. Diabetol. Metab. Syndr. 2014, 6, 96. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Lubas, W.A.; Frank, D.W.; Krause, M.; Hanover, J.A. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J. Biol. Chem. 1997, 272, 9316–9324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Alejandro, E.U.; Bozadjieva, N.; Kumusoglu, D.; Abdulhamid, S.; Levine, H.; Haataja, L.; Vadrevu, S.; Satin, L.S.; Arvan, P.; Bernal-Mizrachi, E. Disruption of O-linked N-Acetylglucosamine Signaling Induces ER Stress and beta Cell Failure. Cell Rep. 2015, 13, 2527–2538. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Dassaye, R.; Naidoo, S.; Cerf, M.E. Transcription factor regulation of pancreatic organogenesis, differentiation and maturation. Islets 2016, 8, 13–34. [Google Scholar] [CrossRef] [Green Version]
  17. Ohlsson, H.; Karlsson, K.; Edlund, T. IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J. 1993, 12, 4251–4259. [Google Scholar] [CrossRef]
  18. Hart, G.W. Nutrient regulation of signaling and transcription. J. Biol. Chem. 2019, 294, 2211–2231. [Google Scholar] [CrossRef] [Green Version]
  19. Gao, Y.; Miyazaki, J.; Hart, G.W. The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in min6 beta-cells. Arch. Biochem. Biophys. 2003, 415, 155–163. [Google Scholar] [CrossRef]
  20. Baumann, D.; Wong, A.; Akhaphong, B.; Jo, S.; Pritchard, S.; Mohan, R.; Chung, G.; Zhang, Y.; Alejandro, E.U. Role of nutrient-driven O-GlcNAc-post-translational modification in pancreatic exocrine and endocrine islet development. Development 2020, 147, dev186643. [Google Scholar] [CrossRef]
  21. Lockridge, A.; Jo, S.; Gustafson, E.; Damberg, N.; Mohan, R.; Olson, M.; Abrahante, J.E.; Alejandro, E.U. Islet O-GlcNAcylation Is Required for Lipid Potentiation of Insulin Secretion through SERCA2. Cell Rep. 2020, 31, 107609. [Google Scholar] [CrossRef] [PubMed]
  22. Lamarre-Vincent, N.; Hsieh-Wilson, L.C. Dynamic glycosylation of the transcription factor CREB: A potential role in gene regulation. J. Am. Chem. Soc. 2003, 125, 6612–6613. [Google Scholar] [CrossRef] [Green Version]
  23. Yang, X.; Ongusaha, P.P.; Miles, P.D.; Havstad, J.C.; Zhang, F.; So, W.V.; Kudlow, J.E.; Michell, R.H.; Olefsky, J.M.; Field, S.J.; et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 2008, 451, 964–969. [Google Scholar] [CrossRef] [PubMed]
  24. Jo, S.; Pritchard, S.; Wong, A.; Avula, N.; Essawy, A.; Hanover, J.; Alejandro, E.U. Pancreatic β-cell hyper-O-GlcNAcylation leads to impaired glucose homeostasis in vivo. Front. Endocrinol. 2022, 13, 1040014. [Google Scholar] [CrossRef]
  25. Akhaphong, B.; Lockridge, A.; Jo, S.; Mohan, R.; Wilcox, J.A.; Wing, C.R.; Regal, J.F.; Alejandro, E.U. Reduced uterine perfusion pressure causes loss of pancreatic β-cell area but normal function in fetal rat offspring. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2018, 315, R1220–R1231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef] [PubMed]
  27. Scaglia, L.; Cahill, C.J.; Finegood, D.T.; Bonner-Weir, S. Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 1997, 138, 1736–1741. [Google Scholar] [CrossRef] [PubMed]
  28. Chera, S.; Baronnier, D.; Ghila, L.; Cigliola, V.; Jensen, J.N.; Gu, G.; Furuyama, K.; Thorel, F.; Gribble, F.M.; Reimann, F.; et al. Diabetes recovery by age-dependent conversion of pancreatic δ-cells into insulin producers. Nature 2014, 514, 503–507. [Google Scholar] [CrossRef] [Green Version]
  29. Mohan, R.; Jo, S.; Da Sol Chung, E.; Oribamise, E.; Lockridge, A.; Abrahante-Lloréns, J.E.; Ruan, H.B.; Yang, X.Y.; Alejandro, E.U. Pancreatic β-Cell O-GlcNAc Transferase Overexpression Increases Susceptibility to Metabolic Stressors in Female Mice. Cells 2021, 10, 2801. [Google Scholar] [CrossRef]
  30. Essawy, A.; Jo, S.; Beetch, M.; Lockridge, A.; Gustafson, E.; Alejandro, E.U. O-linked N-acetylglucosamine transferase (OGT) regulates pancreatic α-cell function in mice. J. Biol. Chem. 2021, 296, 100297. [Google Scholar] [CrossRef] [PubMed]
  31. Rodriguez-Diaz, R.; Molano, R.D.; Weitz, J.R.; Abdulreda, M.H.; Berman, D.M.; Leibiger, B.; Leibiger, I.B.; Kenyon, N.S.; Ricordi, C.; Pileggi, A.; et al. Paracrine Interactions within the Pancreatic Islet Determine the Glycemic Set Point. Cell Metab. 2018, 27, 549–558.e4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Kawamori, D.; Kurpad, A.J.; Hu, J.; Liew, C.W.; Shih, J.L.; Ford, E.L.; Herrera, P.L.; Polonsky, K.S.; McGuinness, O.P.; Kulkarni, R.N. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 2009, 9, 350–361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Huypens, P.; Ling, Z.; Pipeleers, D.; Schuit, F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 2000, 43, 1012–1019. [Google Scholar] [CrossRef] [Green Version]
  34. Herrera, P.L. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development 2000, 127, 2317–2322. [Google Scholar] [CrossRef]
  35. Zhu, Y.; Liu, Q.; Zhou, Z.; Ikeda, Y. PDX1, Neurogenin-3, and MAFA: Critical transcription regulators for beta cell development and regeneration. Stem Cell Res. Ther. 2017, 8, 240. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Ahlgren, U.; Jonsson, J.; Jonsson, L.; Simu, K.; Edlund, H. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 1998, 12, 1763–1768. [Google Scholar] [CrossRef] [Green Version]
  37. Gao, T.; McKenna, B.; Li, C.; Reichert, M.; Nguyen, J.; Singh, T.; Yang, C.; Pannikar, A.; Doliba, N.; Zhang, T.; et al. Pdx1 maintains β cell identity and function by repressing an α cell program. Cell Metab. 2014, 19, 259–271. [Google Scholar] [CrossRef] [Green Version]
  38. Johnson, J.D.; Ahmed, N.T.; Luciani, D.S.; Han, Z.; Tran, H.; Fujita, J.; Misler, S.; Edlund, H.; Polonsky, K.S. Increased islet apoptosis in Pdx1+/− mice. J. Clin. Investig. 2003, 111, 1147–1160. [Google Scholar] [CrossRef]
  39. Wong, A.; Pritchard, S..; Moore, M.; Akhaphong, B.; Avula, N.; Beetch, M.; Fujitani, Y.; Alejandro, E.U. Overexpression of Pdx1, reduction of p53, or deletion of CHOP attenuates pancreas hypoplasia in mice with pancreas-specific O-GlcNAc Transferase deletion. J. Biol. Chem. 2022. [Google Scholar]
  40. Gannon, M.; Ables, E.T.; Crawford, L.; Lowe, D.; Offield, M.F.; Magnuson, M.A.; Wright, C.V. pdx-1 function is specifically required in embryonic beta cells to generate appropriate numbers of endocrine cell types and maintain glucose homeostasis. Dev. Biol. 2008, 314, 406–417. [Google Scholar] [CrossRef] [Green Version]
  41. Wicksteed, B.; Brissova, M.; Yan, W.; Opland, D.M.; Plank, J.L.; Reinert, R.B.; Dickson, L.M.; Tamarina, N.A.; Philipson, L.H.; Shostak, A.; et al. Conditional gene targeting in mouse pancreatic ß-Cells: Analysis of ectopic Cre transgene expression in the brain. Diabetes 2010, 59, 3090–3098. [Google Scholar] [CrossRef] [PubMed]
  42. Lagerlof, O.; Slocomb, J.E.; Hong, I.; Aponte, Y.; Blackshaw, S.; Hart, G.W.; Huganir, R.L. The nutrient sensor OGT in PVN neurons regulates feeding. Science 2016, 351, 1293–1296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Zhao, M.; Xiong, X.; Ren, K.; Xu, B.; Cheng, M.; Sahu, C.; Wu, K.; Nie, Y.; Huang, Z.; Blumberg, R.S.; et al. Deficiency in intestinal epithelial O-GlcNAcylation predisposes to gut inflammation. EMBO Mol. Med. 2018, 10, e8736. [Google Scholar] [CrossRef]
  44. Grarup, N.; Sparsø, T.; Hansen, T. Physiologic characterization of type 2 diabetes-related loci. Curr. Diab. Rep. 2010, 10, 485–497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Schnurr, T.M.; Jakupović, H.; Carrasquilla, G.D.; Ängquist, L.; Grarup, N.; Sørensen, T.I.A.; Tjønneland, A.; Overvad, K.; Pedersen, O.; Hansen, T.; et al. Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: A case-cohort study. Diabetologia 2020, 63, 1324–1332. [Google Scholar] [CrossRef] [PubMed]
  46. Roseboom, T.; de Rooij, S.; Painter, R. The Dutch famine and its long-term consequences for adult health. Early Hum. Dev. 2006, 82, 485–491. [Google Scholar] [CrossRef]
Biomedicines 11 00105 g001 550
Figure 1. No morphological or metabolic changes in OgtKOEndo at birth. At p0: Gross morphology of pancreas, stomach, spleen, and duodenum (A), body weight (B, n = 9–24), pancreas weight (C, n = 9–24), and random blood glucose (D, n = 9–24). Quantification of β-cell mass (E, n = 5–8) and α-cell mass (F, n = 5–8). Representative immunofluorescence images showing normal islet morphology (G, Top row 40×, bottom row 20×, scale = 50 μm). Quantification of apoptosis in β-cells via TUNEL (H, n = 3) with representative images (I, 40×, scale = 100 μm). CAG-EGFP reporter indicates Cre-expression in both β and α-cells (J, 20×, scale = 50 μm). Statistics were performed with a Mann–Whitney U-Test (two-tailed with significance p ≤ 0.05). In all graphs, open circle = Control and closed circle = OgtKOEndo. Both male and female data combined.
Figure 1. No morphological or metabolic changes in OgtKOEndo at birth. At p0: Gross morphology of pancreas, stomach, spleen, and duodenum (A), body weight (B, n = 9–24), pancreas weight (C, n = 9–24), and random blood glucose (D, n = 9–24). Quantification of β-cell mass (E, n = 5–8) and α-cell mass (F, n = 5–8). Representative immunofluorescence images showing normal islet morphology (G, Top row 40×, bottom row 20×, scale = 50 μm). Quantification of apoptosis in β-cells via TUNEL (H, n = 3) with representative images (I, 40×, scale = 100 μm). CAG-EGFP reporter indicates Cre-expression in both β and α-cells (J, 20×, scale = 50 μm). Statistics were performed with a Mann–Whitney U-Test (two-tailed with significance p ≤ 0.05). In all graphs, open circle = Control and closed circle = OgtKOEndo. Both male and female data combined.
Biomedicines 11 00105 g001
Biomedicines 11 00105 g002 550
Figure 2. Progressive hyperglycemia and reduced Pdx1 Immunoreactivity in male OgtKOEndo. Body weight (A, n = 3–11) and random blood glucose (B, n = 3–11) at p15-17. Body weight (C, n = 9–18), pancreas weight (D, n = 8–13), and pancreas weight corrected over body weight (E, n = 8–13, p = 0.1403) at p28. Non-fasting blood glucose levels in OgtKOEndo (F, n = 9–18, **** p < 0.0001) and serum serum insulin (G, n = 5, p = 0.1023) at p28. Quantification of Ins+ area/pancreas area (H, n = 5, * p = 0.0317), β-cell mass (I, n = 5, p = 0.0556), Glucagon+ area/pancreas area (J, n = 4–5, p = 0.0635), and α-cell mass (K, n = 4–5, p = 0.1111) at p28. Representative immunofluorescence images of cytoplasmic Pdx1 expression in OgtKOEndo (L, 20×, scale = 50 μm). Statistics were performed with a Mann–Whitney U-Test (two-tailed with significance p ≤ 0.05). In all graphs, open circle = Control and closed circle = OgtKOEndo. Female data in Supplementary Materials.
Figure 2. Progressive hyperglycemia and reduced Pdx1 Immunoreactivity in male OgtKOEndo. Body weight (A, n = 3–11) and random blood glucose (B, n = 3–11) at p15-17. Body weight (C, n = 9–18), pancreas weight (D, n = 8–13), and pancreas weight corrected over body weight (E, n = 8–13, p = 0.1403) at p28. Non-fasting blood glucose levels in OgtKOEndo (F, n = 9–18, **** p < 0.0001) and serum serum insulin (G, n = 5, p = 0.1023) at p28. Quantification of Ins+ area/pancreas area (H, n = 5, * p = 0.0317), β-cell mass (I, n = 5, p = 0.0556), Glucagon+ area/pancreas area (J, n = 4–5, p = 0.0635), and α-cell mass (K, n = 4–5, p = 0.1111) at p28. Representative immunofluorescence images of cytoplasmic Pdx1 expression in OgtKOEndo (L, 20×, scale = 50 μm). Statistics were performed with a Mann–Whitney U-Test (two-tailed with significance p ≤ 0.05). In all graphs, open circle = Control and closed circle = OgtKOEndo. Female data in Supplementary Materials.
Biomedicines 11 00105 g002
Biomedicines 11 00105 g003 550
Figure 3. Disregulated islet architecture in male p23 OgtKOEndo mice. At p23: Bodyweight (A, n = 8–15), pancreas weight (B, n = 4–6), and pancreas weight corrected over bodyweight (C, n = 4–5). Elevated non-fasting blood glucose (D, n = 8–15, * p = 0.0151) in OgtKOEndo. Serum insulin levels from non-hyperglycemic (BG < 150 mg/dL) OgtKOEndo (E. n = 5–9). Quantification of Insulin+/Pancreas area (F, n = 4–5), β-cell mass (G, n = 4–5), Glucagon+/Pancreas area (H, n = 4–5), α-cell mass (I, n = 4–5), and Glucagon+ cells/islet (J, n = 4–5, * p = 0.0159, quantified over total number of Ins+, Gcg+, and Ins+/Gcg+ cells). Representative images of the islet showing α-cell invasion to the islet core in OgtKOEndo (K, 40×, scale = 50μm). Statistics were performed with a Mann–Whitney U-Test (two-tailed with significance p ≤ 0.05). In all graphs, open circle = Control and closed circle = OgtKOEndo. Female data in Supplementary Materials.
Figure 3. Disregulated islet architecture in male p23 OgtKOEndo mice. At p23: Bodyweight (A, n = 8–15), pancreas weight (B, n = 4–6), and pancreas weight corrected over bodyweight (C, n = 4–5). Elevated non-fasting blood glucose (D, n = 8–15, * p = 0.0151) in OgtKOEndo. Serum insulin levels from non-hyperglycemic (BG < 150 mg/dL) OgtKOEndo (E. n = 5–9). Quantification of Insulin+/Pancreas area (F, n = 4–5), β-cell mass (G, n = 4–5), Glucagon+/Pancreas area (H, n = 4–5), α-cell mass (I, n = 4–5), and Glucagon+ cells/islet (J, n = 4–5, * p = 0.0159, quantified over total number of Ins+, Gcg+, and Ins+/Gcg+ cells). Representative images of the islet showing α-cell invasion to the islet core in OgtKOEndo (K, 40×, scale = 50μm). Statistics were performed with a Mann–Whitney U-Test (two-tailed with significance p ≤ 0.05). In all graphs, open circle = Control and closed circle = OgtKOEndo. Female data in Supplementary Materials.
Biomedicines 11 00105 g003
Biomedicines 11 00105 g004 550
Figure 4. Severe glucose intolerance and loss of β-cell mass in male OgtKOEndo. Representative image of OgtKOEndo at p137 showing robust GFP cre-reporter expression (A, 20×, scale = 100 μm). Pancreas weight (B), and spleen weight (C) at p60. Non-fasting blood glucose levels (D), body weight progression (E), and glucose tolerance test (F) at p60. Quantification of β-cell mass (G) and α-cell mass (H) showing severe reduction in OgtKOEndo at p60. Representative immunofluorescence images of islets at p60 (I, 20×, scale = 100 μm). Statistics were performed with a Mann–Whitney U-Test (two-tailed with significance p ≤ 0.05; * p ≤ 0.05, ** p ≤ 0.01). In all graphs, open circle = Control and closed circle = OgtKOEndo.
Figure 4. Severe glucose intolerance and loss of β-cell mass in male OgtKOEndo. Representative image of OgtKOEndo at p137 showing robust GFP cre-reporter expression (A, 20×, scale = 100 μm). Pancreas weight (B), and spleen weight (C) at p60. Non-fasting blood glucose levels (D), body weight progression (E), and glucose tolerance test (F) at p60. Quantification of β-cell mass (G) and α-cell mass (H) showing severe reduction in OgtKOEndo at p60. Representative immunofluorescence images of islets at p60 (I, 20×, scale = 100 μm). Statistics were performed with a Mann–Whitney U-Test (two-tailed with significance p ≤ 0.05; * p ≤ 0.05, ** p ≤ 0.01). In all graphs, open circle = Control and closed circle = OgtKOEndo.
Biomedicines 11 00105 g004
Biomedicines 11 00105 g005 550
Figure 5. Summary of Ogt loss at various timepoints in pancreas development. Pancreas development begins in the foregut endoderm. A pool of Pdx1+ pancreatic progenitor cells give rise to both the endocrine and exocrine pancres. Deletion of Ogt at the pancreatic progenitor stage leads to pancreatic hypoplasia, in contrast to other models in which Ogt is deleted later in development.
Figure 5. Summary of Ogt loss at various timepoints in pancreas development. Pancreas development begins in the foregut endoderm. A pool of Pdx1+ pancreatic progenitor cells give rise to both the endocrine and exocrine pancres. Deletion of Ogt at the pancreatic progenitor stage leads to pancreatic hypoplasia, in contrast to other models in which Ogt is deleted later in development.
Biomedicines 11 00105 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wong, A.; Akhaphong, B.; Baumann, D.; Alejandro, E.U. Genetic Ablation of the Nutrient Sensor Ogt in Endocrine Progenitors Is Dispensable for β-Cell Development but Essential for Maintenance of β-Cell Mass. Biomedicines 2023, 11, 105. https://doi.org/10.3390/biomedicines11010105

AMA Style

Wong A, Akhaphong B, Baumann D, Alejandro EU. Genetic Ablation of the Nutrient Sensor Ogt in Endocrine Progenitors Is Dispensable for β-Cell Development but Essential for Maintenance of β-Cell Mass. Biomedicines. 2023; 11(1):105. https://doi.org/10.3390/biomedicines11010105

Chicago/Turabian Style

Wong, Alicia, Brian Akhaphong, Daniel Baumann, and Emilyn U. Alejandro. 2023. "Genetic Ablation of the Nutrient Sensor Ogt in Endocrine Progenitors Is Dispensable for β-Cell Development but Essential for Maintenance of β-Cell Mass" Biomedicines 11, no. 1: 105. https://doi.org/10.3390/biomedicines11010105

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop